Musely secures $360M from General Catalyst without giving up equity

```json { "title": "Musely Raises $360M From General Catalyst, Keeps Equity", "metaDescription": "Musely secures $360M in non-dilutive capital from General Catalyst's Customer Value Fund to accelerate customer acquisition without giving up equity.", "content": "<h2>Musely Secures $360M From General Catalyst's Customer Value Fund Without Giving Up Equity</h2><p>Musely, the direct-to-consumer telemedicine company specializing in compounded treatments for skin, hair, and menopause care, has secured $360 million in non-dilutive capital from General Catalyst's Customer Value Fund (CVF), according to TechCrunch (May 1, 2026). The deal is structured as a revenue-share agreement, meaning Musely retains full ownership while using the capital to supercharge customer acquisition — and repays General Catalyst from revenue generated by those funded growth activities.</p><p>The funding represents one of CVF's largest disclosed commitments and arrives as Musely reports average year-over-year revenue growth of 50%, a patient base of over 1.2 million, and a cash burn rate 50 times lower than its peers. The San Jose-based company, founded in 2012 by Jack Jia and Carrie Jiao, has not raised a single dollar of equity capital since a $20 million round led by DCM in 2014.</p><h2>How the Deal Works: Non-Dilutive Capital With a Revenue-Share Structure</h2><p>General Catalyst's Customer Value Fund operates separately from the firm's main venture pool. CVF maintains its own distinct limited partners, and the capital it deploys was not included in General Catalyst's last $8 billion fundraise, according to TechCrunch. The fund has previously backed companies including Grammarly, Lemonade, and Ro.</p><p>The financing structure functions similarly to a revenue-share agreement: companies with predictable revenue streams borrow capital, then repay the funds along with a fixed, capped percentage of revenue generated from the use of General Catalyst's fund. Repayment is tied directly to the performance of the funded sales and marketing activities, with a capped return to General Catalyst, according to InforCapital.</p><p>For Musely, the entire $360 million will be directed toward sales, marketing, and other customer acquisition efforts — not operational overhead or product development. Existing shareholders face no dilution.</p><p>Musely co-founder and CEO Jack Jia was initially skeptical when CVF investors first approached him, according to TechCrunch. After working through the mathematics of the arrangement, his view changed.</p><blockquote><p>"When I mathematically modeled it, I found this absolutely compelling." — Jack Jia, co-founder and CEO of Musely</p></blockquote><p>Jia has spoken candidly about the structural challenge facing capital-efficient DTC companies as they scale. The CVF model, in his view, directly addresses a financing gap that has historically forced high-growth consumer brands to either burn through equity capital or forgo growth.</p><blockquote><p>"When you become a billion-dollar revenue company, you need another billion in order to grow to the next billion." — Jack Jia, co-founder and CEO of Musely</p></blockquote><blockquote><p>"That's why most of the DTC companies, if you look at the capital burn, it is huge." — Jack Jia, co-founder and CEO of Musely</p></blockquote><h2>Musely's Growth Metrics and Business Model</h2><p>Musely allows patients to access prescription products through asynchronous consultations with board-certified dermatologists and OB-GYNs, operating as a telemedicine platform rather than a traditional skincare retailer. Its core offering includes personalized compounded treatments for skin conditions, hair loss, and menopause symptoms.</p><p>The company's growth trajectory has been notable. By late 2024, Musely's revenue was growing at 100% year-over-year, and the company was named the fastest-growing telemedicine brand for the second consecutive year, according to BeautyMatter. From January 2024 to April 2025, Musely fulfilled more than 2.4 million prescription treatments, with retention rates two to three times higher than industry peers and a 95% patient satisfaction rate, according to BeautyMatter.</p><p>In September 2024, a PR Newswire press release noted that Musely had been recognized as the number one fastest-growing tele-dermatology company over the prior four years by Inc. 5000, and described itself as a nine-figure revenue leader. The company has achieved profitability while maintaining a cash burn rate 50 times less than its peers, according to the same press release.</p><p>In September 2025, Musely expanded its product line by launching the Age Well Pill, priced at $45 for a monthly supply, according to BeautyMatter — a sign of its push into the longevity and wellness category alongside its established dermatology and menopause offerings.</p><p>Jia has previously attributed the company's efficiency to its clinical and operational model.</p><blockquote><p>"Musely's rapid ascent in the tele-dermatology industry is a testament to our dedication to innovation and patient care." — Jack Jia, Founder and CEO of Musely</p></blockquote><h2>Why This Deal Matters: Non-Dilutive Financing and the DTC Scaling Problem</h2><p>The Musely-CVF deal reflects a broader shift in how capital-efficient, subscription-oriented consumer health companies approach growth financing. Traditional venture equity is expensive in terms of ownership dilution, while conventional debt instruments are often ill-suited to marketing-heavy DTC businesses whose returns are tied to customer lifetime value rather than hard assets.</p><p>Revenue-based financing models, like the one CVF employs, align repayment with the performance of the specific activities being funded. For a company like Musely — with predictable subscription revenue, high retention rates, and a proven customer acquisition model — the structure offers a way to deploy large amounts of capital into growth without altering the ownership table.</p><p>Musely's ability to go more than a decade without raising equity, while reaching nine-figure revenues and profitability, positions it as an outlier in the DTC health space and likely made it an attractive CVF candidate. The company's metrics — including its 95% patient satisfaction rate and retention rates two to three times above industry peers — suggest a level of revenue predictability that suits the revenue-share repayment structure.</p><p>The deal also signals continued momentum for General Catalyst's CVF strategy. The fund has now backed a roster of high-profile, revenue-generating companies — Grammarly, Lemonade, Ro, and now Musely — using a financing model designed for businesses that have moved past product-market fit and are ready to scale acquisition aggressively. Bloomberg reported in March 2026 that General Catalyst was in talks to raise approximately $10 billion in new funding as part of a broader financial services transformation, suggesting the firm is expanding its capital deployment ambitions significantly.</p><p>The global teledermatology market provides additional context for Musely's growth runway. According to BeautyMatter, the market is projected to reach $41.08 billion by 2030 — a figure that, if accurate, points to substantial headroom for a company that has established a leading position in prescription-based telehealth skincare.</p><h2>What Comes Next for Musely</h2><p>The immediate use of the $360 million is clear: Musely will direct the capital toward sales, marketing, and customer acquisition. The company has not publicly outlined specific campaigns, channel strategies, or target patient growth figures tied to the new capital. What the funding does establish is that Musely intends to accelerate its patient acquisition pace significantly without restructuring its ownership or taking on traditional debt.</p><p>The company's expansion into menopause care and longevity — illustrated by the Age Well Pill launch — suggests Musely is broadening its addressable market beyond dermatology. Whether the CVF capital will be directed toward those newer verticals, its core skincare business, or some combination of both has not been disclosed.</p><p>For General Catalyst, the Musely deal adds a profitable, fast-growing telehealth company to a CVF portfolio that spans productivity software, insurance, and direct-to-consumer health. The structure of the CVF — with distinct limited partners and capital kept separate from the firm's main venture fund — means this deployment does not represent a reallocation of traditional VC dollars, but rather a dedicated pool of growth-financing capital seeking predictable, revenue-generating companies to back.</p><p>For more tech news, visit our <a href=\"/news\">news section</a>.</p><h2>The Health-Tech Angle: Smarter Capital for Patient-Centered Platforms</h2><p>The Musely funding story is not just about a financing structure — it is about what happens when a health platform combines clinical credibility, operational efficiency, and a patient experience strong enough to generate the kind of retention metrics that make non-dilutive growth capital viable. With 1.2 million patients served, 2.4 million prescription treatments fulfilled in just over a year, and satisfaction rates at 95%, Musely has built the kind of data-rich, outcome-oriented health platform that is increasingly attracting non-traditional capital. Staying informed about how health and productivity companies are being built and funded is essential for anyone serious about their own health optimization decisions. Join the <a href=\"/#waitlist\">Moccet waitlist</a> to stay ahead of the curve.</p>", "excerpt": "Musely has secured $360 million in non-dilutive capital from General Catalyst's Customer Value Fund, using a revenue-share structure that lets the telemedicine company scale customer acquisition without giving up equity. The deal arrives as Musely reports 50% average annual revenue growth, over 1.2 million patients served, and a cash burn rate 50 times lower than its peers. CEO Jack Jia, who had not raised equity since a 2014 round, called the financing structure 'absolutely compelling' after modeling its terms.", "keywords": ["Musely funding", "General Catalyst Customer Value Fund", "non-dilutive capital", "teledermatology", "DTC health financing"], "slug": "musely-360m-general-catalyst-non-dilutive-funding" } ```